News on infantile haemangioma. Part 1: clinical course and pathomechanism

Research output: Contribution to journalArticlepeer-review

7 Citations (Scopus)


Currently, there is no doubt that the first choice of treatment for alarming infantile haemangiomas (IHs) is oral beta-blockers. However, research in this field remains active, as the pathogenesis of IH is still not completely elucidated. Furthermore, there are different approaches to the management of IHs with beta-blockers. In Part 1 of this review we will discuss the state-of-the-art evidence for IH with regard to (i) the definition, epidemiology, course, risk factors and sequelae, and (ii) the pathogenesis, focusing on genetic studies. This review will update the reader on the latest developments in the pathogenesis of IH. Furthermore, we hope this review will give more insight into risk factors and sequelae of IH, thereby contributing to better decisions in the clinical management of patients with IH. The therapy and evaluation of IHs will be discussed in Part 2 of this review.

Original languageEnglish
Pages (from-to)473-479
Number of pages7
JournalClinical and Experimental Dermatology
Issue number3
Publication statusPublished - Apr 2021

Bibliographical note

Funding Information:
SJ received unrestricted funding from Pierre Fabre Benelux. The other authors declare that they have no conflicts of interest.

Publisher Copyright:
© 2020 British Association of Dermatologists


  • infantile haemangiomas


Dive into the research topics of 'News on infantile haemangioma. Part 1: clinical course and pathomechanism'. Together they form a unique fingerprint.

Cite this